Evidence map›Paper›PMID 42823962›Full record

ArticleJTO clinical and research reports2026

Living With

Jacques Cadranel, Romain Corre, Peggy Roget, Michael Wingler, Sandrine Alliaume, Pascale Bausson, Leslie Capdevielle, Joana Mendes, Alice Mogenet, Bertrand Mennecier

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jacques CadranelService d'Oncologie Thoracique et Pneumologie, Hôpital Tenon, Paris, France.
Romain CorreService de Pneumologie, CH de Cornouaille, Quimper, France.
Peggy RogetService d'Oncologie Thoracique, CHU de Lille, Lille, France.
Michael WinglerPatients en Reseau-Mon Réseau Cancer du Poumon, Paris, France.
Sandrine AlliaumeAssociation ALK+ ROS1 Cancer Poumon France, Saint-Cyr-au-Mont-d'Or, France.
Pascale BaussonAPLUSA (A+A), Boulogne-Billancourt, France.
Leslie CapdevielleAffaires Médicales, Takeda France, Paris, France.
Joana MendesAffaires Médicales, Takeda France, Paris, France.
Alice MogenetMultidisciplinary Oncology and Therapeutic Innovations Department, Hôpitaux Universitaires de Marseille Nord Chemin des Bourrely, Marseille, France.
Bertrand MennecierDepartment de Pneumologie, CHRU Brabois, Nancy, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The development of ALK inhibitors has transformed the management of Methods: This quantitative, nationwide French survey collated information via online questionnaires from patients ( Results: Overall, 46 patients (54%) had received first-line and 39 patients (46%) second-line or later targeted therapy for a mean of 2.4 years. The most common disease-related challenges reported by patients and HCPs were psychological issues (56.5% and 78.0%), life-planning difficulties (50.6% and 64.0%), and limitations in physical activities of daily life (40.0% and 48.0%), respectively. HCPs consistently underestimated the impact of Conclusions: Our study highlights several measures that can be introduced to reduce disease burden and improve quality of life and, besides routine medical follow-up, markedly improve the overall patient journey through

Indexed as

Anaplastic lymphoma kinaseCaregiversDisease burdenNon–small cell lung cancerPatient-reported outcomes

Identifiers

PMID42823962
PMCPMC13626941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.